HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 06, June 2017 – Advocacies in Support of Rare Disease Patients       » Bayer and NUS Enterprise Announce Winners of Grants4Apps? Singapore Open Innovation Challenge       » Cancer Control Efforts in Vietnam: Interview with Dr Tran Thanh Huong       » China Sets up National Lab Developing Brain-Like AI Technology       » New Womb-Like Invention for Preterm Infants       » World Asthma Day: Managing and Living with Asthma       » Managing Liver Cancer as a Global Health Problem      

BIOBOARD - TAIWAN

Peptide Nasal Spray to Delay Onset of Alzheimer’s disease

Dr. Rita P.-Y. Chen, an Associate Research Fellow at the Institute of Biological Chemistry along with Dr. Pang-hsien Tu, a former Assistant Research Fellow at the Institute of Biomedical Sciences, and their research teams recently found that a modified short peptide delays the onset of Alzheimer’s disease when delivered in the form of a nasal drop in a mouse model. The research was published in EMBO Molecular Medicine on March 29th, 2017.

Dr. Chen, Dr. Tu and colleagues designed a peptide, R8-Aβ(25-35)-PEI, which was able to enter into the brain through the nose and reduce accumulation of Aβ peptide which is widely believed to be a critical determinant of Alzheimer’s disease. Using fluorescence-labeling, the team found that the peptide reached a maximum in the brain at six hours after intranasal administration and the nose-to-brain penetration efficiency was more than 17%. Results from transgenic mouse studies indicated that daily intranasal administration of 6 micrograms of R8-Aβ(25-35)-PEI for 4 months (6 days/week) significantly reduced Aβ amyloid accumulation in the brain and ameliorated memory deficits in APP/PS1 double transgenic mice, a mouse model that expresses mutated amyloid precursor protein and β-secretase, which greatly increase the production of Aβ peptides, especially Aβ42, and therefore mimics Alzheimer’s disease.

Alzheimer’s disease is characterized by neurofibrillary tangles and senile amyloid plaques in the brain. The amyloid plaques are mainly composed of Aβpeptides which are produced in the brain during the catabolism of a protein named amyloid precursor protein (APP). Under normal conditions, Aβ can be degraded by various Aβ-degrading enzymes. However, if the rate of Aβ production exceeds the rate of Aβ degradation, Aβ can accumulate in the brain and form amyloid plaques resulting in the death of neurons. The formation and deposition of amyloid plaques might occur 20 years before clinical onset, hence Aβ is one of the most important targets for the prevention of Alzheimer’s disease.

The number of patients diagnosed with Alzheimer’s disease has significantly increased in recent years due in part to aging populations. Since the average life expectancy after diagnosis with Alzheimer’s varies from 4 to 20 years, medical and non-medical care for Alzheimer’s patients can lead to significant economic and social burdens.

So far, no observable side-effects of the peptide treatment have been observed in the mice, and the rationale of peptide design may also be feasibly applied to other neurodegenerative disorders.

The full research article entitled “An intranasally delivered peptide drug ameliorates cognitive decline in Alzheimer transgenic mice” is available at the EMBO Molecular Medicine website at: http://embomolmed.embopress.org/content/early/2017/03/28/emmm.201606666.long

The complete list of authors is: Yu-Sung Cheng, Zih-ten Chen, Tai-Yan Liao, Chen Lin, Howard C.-H. Shen, Ya-Han Wang, Chi-Wei Chang, Ren-Shyan Liu, Rita P.-Y. Chen*, and Pang-hsien Tu*.

Source: Academia Sinica

Click here for the complete issue.

NEWS CRUNCH  
news The Seventh International Meeting on Synthetic Biology (SB 7.0)
news Healthcare Sustainability in Asia: Now is the Time to Act — FT Asia Healthcare & Life Sciences Summit 2017
news Philip Morris International and British American Tobacco receive award from PETA science group for AOP developments
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Advocacies in Support of Rare Disease Patients
July:
Food Science & Technology
August:
Eye Care/ Eye Health
September:
Emerging Infectious Diseases
October:
No. 1 Killer — Heart Diseases
November:
Diseases threatening our Children
December:
Skin Diseases/Allergic Reactions
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy